Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 32 peer-reviewed journal articles Updated
Neurology

Which RRMS Treatment Schedule Fits My Lifestyle Best?

At a Glance

RRMS treatment schedules include daily or short-course pills, self-injections ranging from daily to every two weeks, and clinic infusions given every four weeks to yearly courses. The right choice depends on disease activity, safety, monitoring, pregnancy plans, and lifestyle.

In this answer

4 sections

01

Oral Medications (Pills)

02

Self-Injections

03

Infusions

04

Balancing Convenience, Efficacy, and Safety

When choosing a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), there is no single “best” schedule for everyone. DMTs are medications that reduce future relapses and new MRI lesions, and they may lower the risk of disability [1][2]. They do not cure MS or reverse existing symptoms.

Options fall into three main administration routes: oral medications (pills), self-injections, and infusions. While a daily pill or a twice-a-year infusion might seem like the easiest choice, convenience is only one part of the picture. The most effective treatment schedule for you depends on your disease activity, medical history, family planning goals, and which side effects and monitoring requirements you can manage safely [3][4]. Treatment strategies are individualized: some patients start with lower-risk therapies and escalate if needed, while those with highly active disease may start immediately with early high-efficacy treatment [3][5].

(Note: The examples below are not exhaustive, and the exact schedule, preparation, and storage instructions are product-specific.)

Oral Medications (Pills)

Pills offer the convenience of avoiding needles. Schedules vary:

  • Daily or twice daily: Options like teriflunomide, fingolimod, and ozanimod are taken once daily [6][7], while dimethyl fumarate is taken twice daily [6].
  • Short courses: Cladribine is given in short oral treatment courses separated by a year [8].

Oral medications require strict adherence. If you miss a dose, do not double up or stop treatment on your own; check your medication instructions and contact your MS care team. Stopping certain oral therapies—especially fingolimod—without a plan can cause a rapid and severe rebound of MS symptoms, where disease activity returns worse than before [9][10].

Monitoring and safety are drug-specific:

  • Baseline screening: Before starting, you may need vaccination review and screening for tuberculosis [11].
  • Ongoing monitoring: You may need an initial observation period to monitor your heart rate for first doses of sphingosine-1-phosphate modulators (like fingolimod or ozanimod) [12][13]. Regular blood tests are often required to check liver function and white blood cell counts [14][15]. Some require regular eye exams [14].
  • Pregnancy: Restrictions are drug-specific. Teriflunomide is not recommended during pregnancy and requires an accelerated drug elimination (washout) procedure if pregnancy occurs [16]. Fingolimod and ozanimod also have fetal-risk restrictions [14].

Self-Injections

Self-injections are given under the skin or into a muscle. Representative examples include:

  • Frequent dosing: Older therapies like glatiramer acetate and interferon beta can be given daily or three times a week [6][17].
  • Less frequent dosing: Peginterferon is injected every two weeks [18].

The main advantage is that they can be administered at home. Older injectables have decades of safety data and are often considered safer during pregnancy compared to some other options, with likely low transfer into breast milk [19].

However, frequent self-injection can cause anxiety and injection-site reactions (like pain, redness, or swelling) [20][21][22]. When traveling, you will need to review specific product instructions, as storage limits and permitted room-temperature periods differ among products; not all require constant refrigeration. While effective, network meta-analyses suggest older injectables generally reduce relapses less than many high-efficacy pills and infusions [1][2].

Infusions

Infusions are administered intravenously at a specialized clinic. Schedules differ drastically:

  • Every four weeks: Natalizumab [23].
  • Every six months: Ocrelizumab (which begins with split initial doses two weeks apart) [24].
  • Yearly courses: Alemtuzumab is given in a 5-day course initially, followed by a 3-day course 12 months later [23][25][26].

Infusions and some newer pills are considered high-efficacy therapies, meaning they are highly effective at reducing relapses and new MRI lesions [1][2]. Because infusions are administered by a healthcare professional, they can reduce the daily burden of taking medication at home.

The trade-off involves clinic travel time, potential immediate infusion reactions [27][22], and complex safety profiles:

  • Baseline screening: May require screening for hepatitis B and C [28]. B-cell-depleting therapies can blunt humoral vaccine responses, so vaccination planning before treatment is critical [29].
  • Progressive Multifocal Leukoencephalopathy (PML): PML is a rare but serious brain infection. This risk is strongly associated with natalizumab [8][30]. Risk assessment is specific to natalizumab and depends on your JC-virus antibody status, prior immunosuppressant use, and duration of treatment. PML risk is much lower with other therapies. Any new, progressive neurologic symptoms should be evaluated urgently.
  • Long-term monitoring: Some infusions require intense ongoing surveillance. For example, alemtuzumab requires strict monthly blood and urine tests for up to four years after your last dose to watch for autoimmune diseases (such as thyroid disorders or immune thrombocytopenia, where your immune system mistakenly attacks your own body) [27][25][26].

Balancing Convenience, Efficacy, and Safety

The easiest schedule is not automatically the safest or most effective choice. Your neurologist will recommend options based on your MRI activity, relapse history, comorbidities, and safety risks [3][4]. Discuss your daily routine, travel habits, pregnancy plans, and comfort with medical monitoring before making a decision [31][32]. Do not stop or change any DMT without discussing it with your MS clinician first.

Common questions in this guide

How do RRMS pills, injections, and infusions differ?
RRMS pills are taken at home daily, twice daily, or in short courses, depending on the medicine. Self-injections may be daily, several times a week, or every two weeks, while infusions are given in a clinic on schedules ranging from every four weeks to yearly courses. The schedule is only one part of choosing treatment; effectiveness, safety, monitoring, and personal preferences also matter.
Is a less frequent RRMS treatment automatically better?
No. A twice-yearly infusion may be more convenient than a daily pill, but convenience does not determine which treatment is safest or most effective for you. Some infusions and newer pills are highly effective, but your neurologist must balance benefits, risks, MRI activity, relapse history, other health conditions, pregnancy plans, and monitoring needs.
What should I do if I miss an RRMS pill or stop treatment?
Do not double the next dose or stop a disease-modifying therapy on your own; check the medication instructions and contact your MS care team. Stopping some medicines, especially fingolimod, without a plan can cause a serious rebound in MS disease activity. Ask what to do if an injection is late or an infusion appointment must be delayed.
What tests and vaccines may be needed before starting an RRMS treatment?
Depending on the medicine, preparation may include reviewing vaccinations and screening for tuberculosis, hepatitis B or C, or JC-virus risk. Blood tests may monitor liver function and white blood cell counts, and some medicines require heart-rate observation or eye exams. Vaccination timing is especially important before treatments that reduce certain immune cells because they can blunt vaccine responses.
How do pregnancy or breastfeeding plans affect RRMS treatment choice?
Pregnancy and breastfeeding plans can change which medicines are appropriate because restrictions differ by drug. Teriflunomide is not recommended during pregnancy and requires a drug-elimination washout if pregnancy occurs, while fingolimod and ozanimod also have fetal-risk restrictions. Some older injectable therapies are often considered safer in pregnancy, but your MS clinician should guide treatment and timing.
Which RRMS treatment schedule works best with work and travel?
The best fit depends on whether you can remember regular pills or injections, attend infusion visits, arrange transportation, and complete lab monitoring. Travel planning should account for product-specific storage and room-temperature rules, because not every injectable needs constant refrigeration. Discuss your routine, work schedule, travel, and needle comfort with your MS care team.

Related questions

Why Are AQP4 and MOG Antibody Tests Used for RRMS? What Diet and Vitamin D Supplements Are Best for RRMS? Can MS Be Diagnosed With a Normal Brain and Spine MRI? Can Relapsing-Remitting MS Progress Without Relapses? CIS vs. Relapsing-Remitting MS: What's the Difference?
Show more
Does Relapsing-Remitting MS Reduce Life Expectancy? How Do I Choose an MS Treatment Strategy for RRMS? How Is Relapsing-Remitting MS Distinguished From Migraine? How Is Secondary Progressive MS Diagnosed After RRMS? How Long Do Relapsing-Remitting MS Medications Take to Work? Is Relapsing-Remitting MS Hereditary? Risk & Testing Does RIS Become Relapsing-Remitting MS or Need Treatment? How Likely Is Another RRMS Relapse, and Can It Be Predicted? Can I Exercise Safely With RRMS and Heat Sensitivity? What Do Oligoclonal Bands and KFLC Mean in MS Diagnosis? What Do the 2024 McDonald Criteria Mean for an MS Diagnosis? What Factors Affect Relapsing-Remitting MS Prognosis? When Should Disease-Modifying Treatment Start for RRMS? When Should I Seek a Second Opinion for RRMS Care?

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (32)
  1. 1

    Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

    Fogarty E, Schmitz S, Tubridy N, et al.

    Multiple sclerosis and related disorders 2016; (9()):23-30.

    PMID: 27645339
  2. 2

    Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.

    Lucchetta RC, Tonin FS, Borba HHL, et al.

    CNS drugs 2018; (32(9)):813-826 doi:10.1007/s40263-018-0541-5.

    PMID: 30014314
  3. 3

    Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.

    Grand'Maison F, Yeung M, Morrow SA, et al.

    Current medical research and opinion 2018; (34(8)):1419-1430 doi:10.1080/03007995.2018.1458023.

    PMID: 29583054
  4. 4

    High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates.

    Inshasi JS, Almadani A, Fahad SA, et al.

    Neurodegenerative disease management 2020; (10(4)):257-266 doi:10.2217/nmt-2020-0016.

    PMID: 32438857
  5. 5

    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.

    Guger M, Enzinger C, Leutmezer F, et al.

    Journal of neurology 2024; (271(6)):3142-3152 doi:10.1007/s00415-024-12256-w.

    PMID: 38430270
  6. 6

    Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.

    Soini E, Joutseno J, Sumelahti ML

    Clinical therapeutics 2017; (39(3)):537-557.e10 doi:10.1016/j.clinthera.2017.01.028.

    PMID: 28209373
  7. 7

    Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

    Cree BAC, Goldman MD, Corboy JR, et al.

    JAMA neurology 2020; doi:10.1001/jamaneurol.2020.2950.

    PMID: 32852530
  8. 8

    Cladribine Tablets: A Review in Relapsing MS.

    Deeks ED

    CNS drugs 2018; (32(8)):785-796 doi:10.1007/s40263-018-0562-0.

    PMID: 30105527
  9. 9

    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

    Roos I, Malpas C, Leray E, et al.

    Neurology 2022; (99(17)):e1926-e1944 doi:10.1212/WNL.0000000000201029.

    PMID: 35977837
  10. 10

    A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

    Sellner J, Rommer PS

    Autoimmunity reviews 2019; (18(3)):255-261 doi:10.1016/j.autrev.2018.09.012.

    PMID: 30639651
  11. 11

    Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting.

    Baldassari LE, Feng J, Macaron G, et al.

    Multiple sclerosis journal - experimental, translational and clinical 2019; (5(3)):2055217319875467 doi:10.1177/2055217319875467.

    PMID: 31588362
  12. 12

    OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

    Ziemssen T, Richter S, Mäurer M, et al.

    Frontiers in neurology 2022; (13()):913616 doi:10.3389/fneur.2022.913616.

    PMID: 35832177
  13. 13

    Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.

    Keenan A, Whichello C, Le HH, et al.

    The patient 2024; (17(6)):685-696 doi:10.1007/s40271-024-00699-2.

    PMID: 38748388
  14. 14

    Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.

    Guarnera C, Bramanti P, Mazzon E

    Drug design, development and therapy 2017; (11()):2193-2207 doi:10.2147/DDDT.S137572.

    PMID: 28814828
  15. 15

    Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.

    Khatri BO

    Therapeutic advances in neurological disorders 2016; (9(2)):130-47 doi:10.1177/1756285616628766.

    PMID: 27006700
  16. 16

    Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report.

    D'Aleo G, Rifici C, Donato A, et al.

    Medicine 2020; (99(28)):e21212 doi:10.1097/MD.0000000000021212.

    PMID: 32664171
  17. 17

    [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].

    Boyko AN, Alifirova VM

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2017; (117(11)):135-139 doi:10.17116/jnevro2017117111135-139.

    PMID: 29265099
  18. 18

    Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update.

    Filipi M, Jack S

    International journal of MS care 2020; (22(4)):165-172 doi:10.7224/1537-2073.2018-063.

    PMID: 32863784
  19. 19

    Treatment of Women with Multiple Sclerosis Planning Pregnancy.

    Krysko KM, Bove R, Dobson R, et al.

    Current treatment options in neurology 2021; (23(4)):11 doi:10.1007/s11940-021-00666-4.

    PMID: 33814892
  20. 20

    GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

    Wolinsky JS, Borresen TE, Dietrich DW, et al.

    Multiple sclerosis and related disorders 2015; (4(4)):370-6.

    PMID: 26195058
  21. 21

    Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients.

    Nicholas J, Ko JJ, Park Y, et al.

    Multiple sclerosis journal - experimental, translational and clinical 2017; (3(1)):2055217317696114 doi:10.1177/2055217317696114.

    PMID: 28607751
  22. 22

    Diagnosis and Treatment of Multiple Sclerosis: A Review.

    McGinley MP, Goldschmidt CH, Rae-Grant AD

    JAMA 2021; (325(8)):765-779 doi:10.1001/jama.2020.26858.

    PMID: 33620411
  23. 23

    Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.

    Foley JF, Defer G, Ryerson LZ, et al.

    The Lancet. Neurology 2022; (21(7)):608-619 doi:10.1016/S1474-4422(22)00143-0.

    PMID: 35483387
  24. 24

    Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.

    AlSharoqi IA, Aljumah M, Bohlega S, et al.

    Neurology and therapy 2020; (9(1)):55-66 doi:10.1007/s40120-020-00187-3.

    PMID: 32297127
  25. 25

    Alemtuzumab in multiple sclerosis: an update.

    Gross RH, Krieger S

    Neurodegenerative disease management 2015; (5(3)):225-32 doi:10.2217/nmt.15.14.

    PMID: 26107321
  26. 26

    Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

    Berger T, Elovaara I, Fredrikson S, et al.

    CNS drugs 2017; (31(1)):33-50 doi:10.1007/s40263-016-0394-8.

    PMID: 27882532
  27. 27

    Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

    Havrdova E, Horakova D, Kovarova I

    Therapeutic advances in neurological disorders 2015; (8(1)):31-45 doi:10.1177/1756285614563522.

    PMID: 25584072
  28. 28

    The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

    Biolato M, Bianco A, Lucchini M, et al.

    CNS drugs 2021; (35(8)):861-880 doi:10.1007/s40263-021-00842-9.

    PMID: 34319570
  29. 29

    Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.

    Starvaggi Cucuzza C, Longinetti E, Ruffin N, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(1)) doi:10.1212/NXI.0000000000200056.

    PMID: 36411076
  30. 30

    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

    Rae-Grant A, Day GS, Marrie RA, et al.

    Neurology 2018; (90(17)):777-788 doi:10.1212/WNL.0000000000005347.

    PMID: 29686116
  31. 31

    The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

    Webb EJD, Meads D, Eskytė I, et al.

    The patient 2020; (13(5)):583-597 doi:10.1007/s40271-020-00429-4.

    PMID: 32588337
  32. 32

    Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.

    Inshasi JS, Alfahad S, Alsaadi T, et al.

    Neurology and therapy 2021; (10(2)):435-454 doi:10.1007/s40120-021-00243-6.

    PMID: 33891277

This page compares RRMS treatment schedules for educational purposes and does not replace medical advice. Your neurologist or MS care team can help choose and safely monitor a therapy for your situation.